Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 28,902 shares of the stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $1.72, for a total value of $49,711.44. Following the transaction, the chief financial officer now directly owns 231,744 shares of the company's stock, valued at approximately $398,599.68. The trade was a 11.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Matt Zuga also recently made the following trade(s):
- On Tuesday, January 21st, Matt Zuga sold 4,364 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.60, for a total value of $6,982.40.
- On Friday, January 3rd, Matt Zuga sold 13,235 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.84, for a total value of $24,352.40.
Acumen Pharmaceuticals Price Performance
Shares of NASDAQ ABOS traded down $0.02 during trading on Thursday, hitting $1.73. The company had a trading volume of 335,357 shares, compared to its average volume of 378,633. Acumen Pharmaceuticals, Inc. has a 52 week low of $1.53 and a 52 week high of $5.09. The business's 50-day moving average is $1.96 and its 200 day moving average is $2.46. The company has a market cap of $103.94 million, a P/E ratio of -1.25 and a beta of 0.02. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43.
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.14). During the same period in the prior year, the business earned ($0.24) earnings per share. Equities research analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.
Get Our Latest Stock Report on ABOS
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Acumen Pharmaceuticals during the third quarter valued at approximately $44,000. American Century Companies Inc. grew its position in Acumen Pharmaceuticals by 31.3% during the 2nd quarter. American Century Companies Inc. now owns 45,444 shares of the company's stock worth $110,000 after purchasing an additional 10,840 shares in the last quarter. Rhumbline Advisers acquired a new stake in Acumen Pharmaceuticals during the 2nd quarter valued at $127,000. Murchinson Ltd. purchased a new stake in shares of Acumen Pharmaceuticals in the second quarter valued at $136,000. Finally, Barclays PLC grew its holdings in shares of Acumen Pharmaceuticals by 189.1% during the third quarter. Barclays PLC now owns 61,997 shares of the company's stock valued at $154,000 after buying an additional 40,551 shares in the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.
Acumen Pharmaceuticals Company Profile
(
Get Free Report)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Acumen Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.
While Acumen Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
